-
公开(公告)号：US09771579B2
公开(公告)日：2017-09-26
申请号：US13805745
申请日：2011-06-23
IPC分类号： C12N15/11 , C12N15/113 , A61K31/7088 , C12Q1/68
CPC分类号： C12N15/113 , A61K31/7088 , C12N15/1138 , C12N2310/111 , C12N2310/113 , C12N2310/315 , C12Q1/6813 , C12N2330/10
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sodium channel, voltage-gated, alpha subunit (SCNA), in particular, by targeting natural antisense polynucleotides of Sodium channel, voltage-gated, alpha subunit (SCNA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SCNA.
-
2.发明申请TREATMENT OF SODIUM CHANNEL, VOLTAGE-GATED, ALPHA SUBUNIT (SCNA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SCNA 有权通过抑制自然抗原转录物到SCNA，治疗钠通道，电压门控，ALPHA亚型（SCNA）相关疾病公开(公告)号：US20130096183A1
公开(公告)日：2013-04-18
申请号：US13805745
申请日：2011-06-23
IPC分类号： C12N15/113 , C12Q1/68
CPC分类号： C12N15/113 , A61K31/7088 , C12N15/1138 , C12N2310/111 , C12N2310/113 , C12N2310/315 , C12Q1/6813 , C12N2330/10
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sodium channel, voltage-gated, alpha subunit (SCNA), in particular, by targeting natural antisense polynucleotides of Sodium channel, voltage-gated, alpha subunit (SCNA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SCNA.
摘要翻译： 本发明涉及调节钠通道，电压门控α亚基（SCNA）的表达和/或功能的反义寡核苷酸，特别是通过靶向钠通道，电压门控的α亚基（SCNA）的天然反义多核苷酸 ）。 本发明还涉及这些反义寡核苷酸的鉴定及其在治疗与SCNA表达相关的疾病和病症中的用途。
-
公开(公告)号：US10583128B2
公开(公告)日：2020-03-10
申请号：US14343890
申请日：2012-08-28
IPC分类号： A61K31/7048 , A61K31/4545 , A61K31/496 , A61K31/58 , A61K31/495 , A61K31/5513 , A61K31/436 , A61K31/5375 , A61K31/519 , A61K31/4985 , A61K31/4409 , A61K31/4439 , A61K31/4422 , A61K31/365 , A61K31/64 , A61K31/41 , A61K31/135 , A61K31/165 , A61K31/4245
摘要： Small compounds that modulate the expression of and/or function of sodium channel, voltage-gated, alpha subunit (SCNxA) are presented. Pharmaceutical compositions containing such small molecules and their use in treating diseases and disorders associated with the expression of SCNxA are also presented.
-
4.发明授权Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS) 有权通过抑制胰岛素基因（INS）的天然反义转录物治疗胰岛素基因（INS）相关疾病公开(公告)号：US09234199B2
公开(公告)日：2016-01-12
申请号：US13388767
申请日：2010-08-05
IPC分类号： C07H21/04 , A61K48/00 , A61K31/7088 , C12N15/113 , A61K31/713
CPC分类号： C12N15/1136 , A61K31/713 , C12N2310/11 , C12N2310/111 , C12N2310/113 , C12Q1/6883 , C12Q2600/136 , G06F19/22
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of an Insulin gene (INS), in particular, by targeting natural antisense polynucleotides of an Insulin gene (INS). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Insulin Gene (INS).
摘要翻译： 本发明涉及调节胰岛素基因（INS）表达和/或功能的反义寡核苷酸，特别是通过靶向胰岛素基因（INS）的天然反义多核苷酸。 本发明还涉及这些反义寡核苷酸的鉴定及其在治疗与胰岛素基因（INS）表达相关的疾病和病症中的用途。
-
5.发明授权Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA 有权通过抑制天然反义转录物到MSRA，治疗甲硫氨酸亚砜还原酶a（MSRA）相关疾病公开(公告)号：US08980858B2
公开(公告)日：2015-03-17
申请号：US13699356
申请日：2011-05-25
IPC分类号： A61K48/00 , C07H21/02 , C07H21/04 , A61K31/713 , C12N9/02 , C12N15/113
CPC分类号： C12N15/1137 , A61K31/713 , C12N9/0051 , C12N15/113 , C12N2310/11 , C12N2310/111 , C12N2310/113 , C12N2310/315 , C12N2330/10 , C12Y108/04011
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Methionine Sulfoxide Reductase A (MSRA), in particular, by targeting natural antisense polynucleotides of Methionine Sulfoxide Reductase A (MSRA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of MSRA.
摘要翻译： 本发明涉及通过靶向甲硫氨酸亚砜还原酶A（MSRA）的天然反义多核苷酸来调节甲硫氨酸亚砜还原酶A（MSRA）的表达和/或功能的反义寡核苷酸。 本发明还涉及这些反义寡核苷酸的鉴定及其在治疗与MSRA表达相关的疾病和病症中的用途。
-
6.发明授权Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63 有权通过抑制p63的天然反义转录物治疗肿瘤蛋白63（p63）相关疾病公开(公告)号：US08962585B2
公开(公告)日：2015-02-24
申请号：US13519477
申请日：2010-12-29
IPC分类号： C12N15/11 , C12N15/113 , A61K31/7088
CPC分类号： C12N15/113 , A61K31/7088 , C12N15/1135 , C12N2310/11 , C12N2310/113 , C12N2310/31 , C12N2310/315 , C12N2310/32 , C12N2310/321 , C12N2310/3231 , C12N2310/33 , C12Q1/6811
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Protein 63 (p63), in particular, by targeting natural antisense polynucleotides of Tumor Protein 63 (p63). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of p63.
摘要翻译： 本发明涉及调节肿瘤蛋白63（p63）的表达和/或功能的反义寡核苷酸，特别是通过靶向肿瘤蛋白63（p63）的天然反义多核苷酸。 本发明还涉及这些反义寡核苷酸的鉴定及其在治疗与p63表达相关的疾病和病症中的用途。
-
7.发明授权Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor 有权通过将天然反义转录物抑制到重编程因子来治疗重编程因子相关疾病公开(公告)号：US08957037B2
公开(公告)日：2015-02-17
申请号：US13320637
申请日：2010-05-18
CPC分类号： C12N15/113 , A61K31/713 , C12N15/111 , C12N2310/11 , C12N2310/113 , C12N2310/14 , C12N2310/31 , C12N2310/312 , C12N2310/313 , C12N2310/314 , C12N2310/315 , C12N2310/316 , C12N2310/3181 , C12N2310/32 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2320/30
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Reprogramming factor, in particular, by targeting natural antisense polynucleotides of a Reprogramming factor. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Reprogramming factors.
摘要翻译： 本发明涉及调节重编程因子的表达和/或功能的反义寡核苷酸，特别是通过靶向重编程因子的天然反义多核苷酸。 本发明还涉及这些反义寡核苷酸的鉴定及其在治疗与重编程因子表达相关的疾病和病症中的用途。
-
8.发明授权Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1 有权通过抑制ATOH1的天然反义转录物来治疗无性同系物1（ATOH1）相关疾病公开(公告)号：US08895528B2
公开(公告)日：2014-11-25
申请号：US13699346
申请日：2011-05-25
CPC分类号： C12N15/113 , A61K31/7125 , A61K31/713 , C07K2/00 , C12N2310/11 , C12N2310/111 , C12N2310/113 , C12N2310/312 , C12N2310/313 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/3521 , C12N2310/3525 , C12N2310/3533 , Y02A50/401 , C12N2330/10
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Atonal homolog 1 (ATOH1), in particular, by targeting natural antisense polynucleotides of Atonal homolog 1 (ATOH1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of ATOH1.
摘要翻译： 本发明涉及调节Atonal同系物1（ATOH1）的表达和/或功能的反义寡核苷酸，特别是通过靶向Atonal同系物1（ATOH1）的天然反义多核苷酸。 本发明还涉及这些反义寡核苷酸的鉴定及其在治疗与ATOH1表达相关的疾病和病症中的用途。
-
9.发明授权Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3 有权转录因子E3（TFE3）和胰岛素受体底物2（IRS2）相关疾病的治疗通过天然反义转录物抑制TFE3公开(公告)号：US08895527B2
公开(公告)日：2014-11-25
申请号：US13321863
申请日：2010-05-21
IPC分类号： C12N15/11 , A61K31/713 , C12N15/113
CPC分类号： C12N15/113 , A61K31/713 , C12N2310/113 , C12Q1/6825
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Transcription factor E3 (TFE3) and/or Insulin Receptor Substrate 2 (IRS2) polynucleotides, in particular, by targeting natural antisense polynucleotides of Transcription factor E3 (TFE3) and/or Insulin Receptor Substrate 2 (IRS2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of TFE3 and/or IRS2.
摘要翻译： 本发明涉及调节转录因子E3（TFE3）和/或胰岛素受体底物2（IRS2）多核苷酸的表达和/或功能的反义寡核苷酸，特别是通过靶向转录因子E3（TFE3）的天然反义多核苷酸， 和/或胰岛素受体底物2（IRS2）。 本发明还涉及这些反义寡核苷酸的鉴定及其在治疗与TFE3和/或IRS2的表达相关的疾病和病症中的用途。
-
10.发明授权Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2 有权通过抑制TNFR2的天然反义转录物治疗肿瘤坏死因子受体2（TNFR2）相关疾病公开(公告)号：US08859515B2
公开(公告)日：2014-10-14
申请号：US13379728
申请日：2010-06-24
IPC分类号： A61K31/70 , C07H21/02 , C07H21/04 , C12N15/113 , A61K31/711 , C12Q1/68
CPC分类号： C12N15/1138 , A61K31/711 , C12N2310/11 , C12N2310/111 , C12N2310/113 , C12N2320/30
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Necrosis Factor Receptor 2 (TNFR2), in particular, by targeting natural antisense polynucleotides of Tumor Necrosis Factor Receptor 2 (TNFR2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of TNFR2.
摘要翻译： 本发明涉及调节肿瘤坏死因子受体2（TNFR2）的表达和/或功能的反义寡核苷酸，特别是通过靶向肿瘤坏死因子受体2（TNFR2）的天然反义多核苷酸。 本发明还涉及这些反义寡核苷酸的鉴定及其在治疗与TNFR2表达相关的疾病和病症中的用途。
-
-
-
-
-
-
-
-
-
搜索结果
90 条记录 (耗时 0.056 秒)
